Long-term Outcomes in Primary CNS Lymphoma Following R-MVP and High Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplant.
Kate Elizabeth TherkelsenLauren R SchaffSubhiksha NandakumarAntonio M P OmuroLisa M DeAngelisChristian GrommesPublished in: Neurology (2023)
Long-term follow up demonstrated that treatment was well tolerated in most patients enrolled in this study, with stable leukoencephalopathy on imaging and stable clinical performance status. Disease recurrence was not observed beyond 2 years after HDC-ASCT consolidation.
Keyphrases
- high dose
- hematopoietic stem cell
- ejection fraction
- newly diagnosed
- high resolution
- low dose
- bone marrow
- diffuse large b cell lymphoma
- squamous cell carcinoma
- patient reported outcomes
- blood brain barrier
- mass spectrometry
- free survival
- patient reported
- stem cell transplantation
- replacement therapy
- platelet rich plasma